American Society of Clinical Oncology

SHERPA: White

People

  1. Zelenetz
    Zelenetz
  2. Noy
    Noy
  3. Panageas
    Panageas
  4. Scheinberg
    Scheinberg
  5. Palomba
    Palomba

Groups

  1. Center for Hematologic Malignancies (6)
  2. Department of Medicine (6)
  3. Hematologic Malignancies, Division of (6)
  4. Lymphoma (6)
  5. Adult Leukemia (3)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (2)
  7. Biostatistics Service (2)
  8. Epidemiology and Biostatistics (2)
  9. GSK Faculty (2)
  10. Hematologic Malignancies Research (2)
Search Within
  1. "Lymphoma"
  2. "Nicole Lamanna"
Formats
  1. Meeting Abstract (4)
  2. Journal Article (2)
Groups
  1. Center for Hematologic Malignancies (6)
  2. Department of Medicine (6)
  3. Hematologic Malignancies, Division of (6)
  4. Lymphoma (6)
  5. Adult Leukemia (3)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (2)

More Groups

People
  1. Nicole Lamanna (6)
  2. Andrew Zelenetz (5)
  3. Joseph Jurcic (3)
  4. Mark Heaney (3)
  5. Peter Maslak (3)
  6. Alison Gencarelli (2)

More People

Years
  1. 2014 (2)
  2. 2013 (1)
  3. 2012 (1)
  4. 2009 (1)
  5. 2006 (1)
Publications
  1. Journal of Clinical Oncology (6)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results
    Meeting Abstract

    Ghia, P.; O'Brien, S. M.; Hillmen, P.; Furman, R. R.; Coutre, S. E.; Sharman, J. P.; Cheson, B. D.; Pagel, J. M.; Barrientos, J. C.; Zelenetz, A. D.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL
    Meeting Abstract

    Coutre, S. E.; Furman, R. R.; Sharman, J. P.; Cheson, B. D.; Pagel, J. M.; Hillmen, P.; Barrientos, J. C.; Zelenetz, A. D.; Kipps, T. J.; Flinn, I.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥ 65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
    Meeting Abstract

    O'Brien, S. M.; Lamanna, N.; Kipps, T. J.; Flinn, I.; Zelenetz, A. D.; Burger, J. A.; Holes, L.; Johnson, D. M.; Gu, J.; Dansey, R. D.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A new paradigm in CLL: Minimizing toxicity by using the minimum effective dose (MED) of lenalidomide for older patients with CLL
    Meeting Abstract

    Lamanna, N.; Heaney, M. L.; Maslak, P. G.; Jurcic, J. G.; Rosenblat, T. L.; Noy, A.; Palomba, M. L.; Weiss, M. A.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: Molecular remissions predict for durable complete responses
    Journal Article

    Lamanna, N.; Jurcic, J. G.; Noy, A.; Maslak, P.; Gencarelli, A. N.; Panageas, K. S.; Heaney, M. L.; Brentjens, R. J.; Golde, D. W.; Scheinberg, D. A.; more...
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia
    Journal Article

    Lamanna, N.; Kalaycio, M.; Maslak, P.; Jurcic, J. G.; Heaney, M.; Brentjens, R.; Zelenetz, A. D.; Horgan, D.; Gencarelli, A.; Panageas, K. S.; more...
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save